Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.
Coerver EME, Fung WH, de Beukelaar J, Bouvy WH, Canta LR, Gerlach OHH, Hoitsma E, Hoogervorst ELJ, de Jong BA, Kalkers NF, van Kempen ZLE, Lövenich H, van Munster CEP, van Oosten BW, Smolders J, Vennegoor A, Zeinstra EMPE, Barrantes-Cepas M, Kooij G, Schoonheim MM, Lissenberg-Witte BI, Teunissen CE, Moraal B, Barkhof F, Uitdehaag BMJ, Mostert J, Killestein J, Strijbis EMM. Coerver EME, et al. Among authors: killestein j. JAMA Neurol. 2024 Dec 9. doi: 10.1001/jamaneurol.2024.4164. Online ahead of print. JAMA Neurol. 2024. PMID: 39652340
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
Hartung HP, Benedict RHB, Berger T, Bermel RA, Brochet B, Carroll WM, Freedman MS, Holmøy T, Karabudak R, Nos C, Patti F, Perrin Ross A, Vanopdenbosch L, Vollmer T, Wuerfel J, Clinch S, Kadner K, Kuenzel T, Kulyk I, Raposo C, Thanei GA, Killestein J. Hartung HP, et al. Among authors: killestein j. Neurology. 2024 Dec 24;103(12):e210049. doi: 10.1212/WNL.0000000000210049. Epub 2024 Dec 3. Neurology. 2024. PMID: 39626127 Clinical Trial.
Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis.
Brownlee WJ, Vidal-Jordana A, Shatila M, Strijbis E, Schoof L, Killestein J, Barkhof F, Bollo L, Rovira A, Sastre-Garriga J, Tintore M, Rocca MA, Esposito F, Azzimonti M, Filippi M, Bodini B, Lazzarotto A, Stankoff B, Montalban X, Toosy AT, Thompson AJ, Ciccarelli O; MAGNIMS Study Group. Brownlee WJ, et al. Among authors: killestein j. Ann Neurol. 2024 Nov 28. doi: 10.1002/ana.27145. Online ahead of print. Ann Neurol. 2024. PMID: 39605172
Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy.
Caballero-Ávila M, Martín-Aguilar L, Pascual-Goñi E, Michael MR, Koel-Simmelink MJA, Höftberger R, Wanschitz J, Alonso-Jiménez A, Armangué T, Baars AE, Carbayo Á, Castek B, Collet-Vidiella R, De Winter J, Del Real MÁ, Delmont E, Diamanti L, Doneddu PE, Hiew FL, Gallardo E, Gonzalez A, Grinzinger S, Horga A, Iglseder S, Jacobs BC, Jauregui A, Killestein J, Pozza EL, Martínez-Martínez L, Nobile-Orazio E, Ortiz N, Pérez-Pérez H, Poppert KN, Ripellino P, Roche JC, Rodriguez de Rivera FJ, Rostasy K, Sparasci D, Tejada-Illa C, Teunissen CCE, Vegezzi E, Xuclà-Ferrarons T, Zach F, Wieske L, Eftimov F, Lleixà C, Querol L. Caballero-Ávila M, et al. Among authors: killestein j. Ann Neurol. 2024 Nov 27. doi: 10.1002/ana.27142. Online ahead of print. Ann Neurol. 2024. PMID: 39601182
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
Toorop AA, Wessels MH, Boonkamp L, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, van Munster CE, Vennegoor A, Mostert JP, Wokke BH, Kalkers NF, Hoogervorst EL, van Eijk JJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige L, Kloosterziel ME, Arnoldus EP, van Dijk GW, Bouvy WH, Strijbis EM, van Oosten BW, de Jong BA, Uitdehaag BM, Rispens T, Killestein J, van Kempen ZL, Teunissen CE. Toorop AA, et al. Among authors: killestein j. Mult Scler. 2024 Nov;30(13):1683-1688. doi: 10.1177/13524585241293940. Epub 2024 Nov 4. Mult Scler. 2024. PMID: 39494701 Free PMC article.
Intrathecal IgG and IgM synthesis correlates with neurodegeneration markers and corresponds to meningeal B cell presence in MS.
Rodriguez-Mogeda C, van Gool MM, van der Mast R, Nijland R, Keasberry Z, van de Bovekamp L, van Delft MA, Picon C, Reynolds R, Killestein J, Teunissen CE, de Vries HE, van Egmond M, Witte ME. Rodriguez-Mogeda C, et al. Among authors: killestein j. Sci Rep. 2024 Oct 26;14(1):25540. doi: 10.1038/s41598-024-76969-8. Sci Rep. 2024. PMID: 39462090 Free PMC article.
9-HODE associates with thalamic atrophy and predicts white matter damage in multiple sclerosis.
Fung WH, van Lingen MR, Broos JY, Lam KH, van Dam M, Fung WK, Noteboom S, Koubiyr I, de Vries HE, Jasperse B, Teunissen CE, Giera M, Killestein J, Hulst HE, Strijbis EMM, Schoonheim MM, Kooij G. Fung WH, et al. Among authors: killestein j. Mult Scler Relat Disord. 2024 Dec;92:105946. doi: 10.1016/j.msard.2024.105946. Epub 2024 Oct 16. Mult Scler Relat Disord. 2024. PMID: 39447246 Free article.
COVID-19 and multiple sclerosis: challenges and lessons for patient care.
Prosperini L, Arrambide G, Celius EG, Goletti D, Killestein J, Kos D, Lavorgna L, Louapre C, Sormani MP, Stastna D, Ziemssen T, Di Filippo M. Prosperini L, et al. Among authors: killestein j. Lancet Reg Health Eur. 2024 Aug 22;44:100979. doi: 10.1016/j.lanepe.2024.100979. eCollection 2024 Sep. Lancet Reg Health Eur. 2024. PMID: 39429966 Free PMC article. Review.
Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.
van Lierop ZY, Wessels MH, Lekranty WM, Moraal B, Hof SN, Hogenboom L, de Jong BA, Meijs N, Mensing LA, van Oosten BW, Sol N, van Kempen ZL, Vermunt L, Willems MJ, Strijbis EM, Uitdehaag BM, Killestein J, Teunissen CE. van Lierop ZY, et al. Among authors: killestein j. Mult Scler. 2024 Nov;30(13):1620-1629. doi: 10.1177/13524585241277044. Epub 2024 Oct 17. Mult Scler. 2024. PMID: 39420574 Free PMC article.
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter GR, Giovannoni G, Killestein J, Wiendl H, Li K, Dsilva L, Toukam M, Ferber K, Sohn J, Engelman H, Lasky T. Foley JF, et al. Among authors: killestein j. Neurol Neuroimmunol Neuroinflamm. 2024 Dec;11(6):e200321. doi: 10.1212/NXI.0000000000200321. Epub 2024 Oct 11. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 39393045 Free PMC article. Clinical Trial.
330 results